Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab

NEXT STORY
GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
PREV STORY
Worldwide Aminoglycosides Markets, 2019 to 2024: Expiry of Patent Exclusivity has Led to Large Scale Generic Manufacturing of Aminoglycosides, Particularly in the Developing Region of Asia-Pacific
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab

NEXT STORY
GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
PREV STORY
Worldwide Aminoglycosides Markets, 2019 to 2024: Expiry of Patent Exclusivity has Led to Large Scale Generic Manufacturing of Aminoglycosides, Particularly in the Developing Region of Asia-Pacific
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New to The Street / Newsmax TV Announces 8 Interviews for This Week’s TV Broadcast, Sunday, August 22, 2021, Hour Slot 10-11 AM ET

author_avatar
NASDAQ Market News

ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System

author_avatar
NASDAQ Market News

Cellectar Biosciences To Present at BIO Investor Forum

MADISON, Wis., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), ...

author_avatar
NASDAQ Market News